Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Investor Presentation (May 2023)
32 slides from Marinomed Biotech's investor presentation, May 15, 2023
Slide 1: Marinomed Biotech AG
Marinomed Biotech AG Andreas Grassauer, CEO May 2023
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Company
Company Overview, Business Model, Equity Story © Marinomed Biotech AG 3
Slide 4: Marinomed at a glance
Marinomed at a glance Publicly listed biopharmaceutical company located in Korneuburg, Austria 2006 2008 2016 2019 2021 Foundation Launch of Invention of IPO and Marinosolv Marinosolv deal Carragelose Marinosolv clinical validation and Solv4U launch 13.5% Acropora Beteiligungs GmbH Business Segments
Slide 5: Equity Story
Equity Story Solid existing business, broad late-stage pipeline • Experienced management team • Solid revenue from marketed product portfolio and long-term growth perspective with maturing pipeline • Low clinical and regulatory risk: late-stage development and commercialization with partners lowers
Slide 6: Highlights 2022
Highlights 2022 Delivering on our promises EUR 11.3 m + 15.5% Deal Marinosolv Stable revenues Successful year for Increase in Carragelose Solv4U Carragelose deal with Procter & + 16.5% adjusted for revenues Gamble for the U.S. Budesolv milestone U.S. patent granted © Marinomed Biotech AG 6
Slide 7: Therapeutic Areas, Pipeline
Therapeutic Areas, Pipeline © Marinomed Biotech AG 7
Slide 8: Therapeutic Areas
Therapeutic Areas Proven track record with clinically validated and patent protected technologies VIROLOGY IMMUNOLOGY • Iota-carrageenan from red seaweed: • Marinosolv technology: solubilization for broad-spectrum virus blocker hydrophobic compounds • Clinically validated efficacy against Suspension
Slide 9: Carragelose
Carragelose Expertise in Virology – brought to market Mode of action Partner Logos (samples) Carragelose effect Protective layer Carragelose covers the viral surface unspecifically Product pictures (sample) Prophylactic and therapeutic efficacy clinically validated Baltics Broadly active across seve
Slide 10: Marinomed Strategy
Marinomed Strategy Building on solid existing business, entering new markets 2023+ 2023/24 2025+ • Maximize revenue • Expand in OTC • Expand in Rx • Geographical expansion • Geographical expansion • Progressing technology partnerships Tacrosolv Inflammatory eye diseases Future revenue Inhaleen Viral
Slide 11: Pipeline
Pipeline Late-stage projects with low risk and high upside potential © Marinomed Biotech AG 11
Slide 12: Marinomed Strategy
Marinomed Strategy Building on solid existing business, entering new markets 2023+ 2023/24 2025+ • Maximize revenue • Expand in OTC • Expand in Rx • Geographical expansion • Geographical expansion • Progressing technology partnerships Tacrosolv Inflammatory eye diseases Future revenue Inhaleen Viral
Slide 13: Tacrosolv (MAM-1003-1)
Tacrosolv (MAM-1003-1) Best-in-class macrolide immunosuppressant – fully solubilized with Marinosolv Solubilized Tacrolimus (Liquid formulation) Micelle-enabled solubilization Tacrolimus (FK506) Tacrosolv • Macrolide calcineurin inhibitor used for • Fully solubilized Tacrolimus immunosuppression, e.
Slide 14: Tacrosolv validated in clinical phase II trial
Tacrosolv validated in clinical phase II trial1 Anti-inflammatory activity in model indication allergic conjunctivitis shown1 Significant reduction of TOSS2 26% reduction of TOSS2 on day SIGNIFICANT REDUCTION4 on day 8 compared to placebo 14 8 within Tacrosolv study • of ocular symptoms on day 8 of
Slide 15: Attractive ophthalmic market
Attractive ophthalmic market Total target populations & market sizes Tacrosolv Allergic Herpetic stromal Vernal Dry eye disease conjunctivitis keratitis (HSK) keratoconjunctivitis US 49mn1 US 50mn4 US 18k7 US 33k7 EU5 59mn2 EU5 60mn5 EU5 18k7 EU5 162k7 US$ 6.5bn (2027)3 US$ 3.6bn (2028)6 US$ 300mn8
Slide 16: Marinomed Strategy
Marinomed Strategy Building on solid existing business, entering new markets 2023+ 2023/24 2025+ • Maximize revenue • Expand in OTC • Expand in Rx • Geographical expansion • Geographical expansion • Progressing technology partnerships Tacrosolv Inflammatory eye diseases Future revenue Inhaleen Viral
Slide 17: Clinical trial with decongestant medical device
Clinical trial with decongestant medical device Screened N = 46 Did not fulfill Inclusion / exclusion criteria (N = 5) Safety Population Full analysis set (FAS) Intention to treat set (ITT) N = 41 Discontinued N = 1 (Study period 1) Completed allergy N = 1 (Study period 2) challenge N = 39 Non-respo
Slide 18: Coldamaris akut (Carrageenan/Sorbitol combi)
Coldamaris akut (Carrageenan/Sorbitol combi) Significant improvement of nasal airflow Nasal airflow: treatment effect p=0.039 70 60 50 p<0.05 40 30 20 10 0 better / equal worse Coldamaris akut Placebo In total, 60% of the subjects had a benefit from treatment while 40% experienced no improvement (p<
Slide 19: Clinical trial with Carragelose in allergy
Clinical trial with Carragelose in allergy Screened N = 47 Did not fulfill Inclusion / exclusion criteria; excluded by study site (N = 5) Full analysis set (FAS) Intention to treat set (ITT) N = 42 Discontinued N=0 Completed allergy challenge N = 42 Non-responder N=0 Per protocol set (PP) N = 42 © M
Slide 20: Carragelose in allergy: Buffered Carragelose
Carragelose in allergy: Buffered Carragelose Significantly reduced symptoms TNSS median 180 min Rhinorrhea 9.1 2.2 8.9 2.1 8.7 p=0.028 2 p<0.05 Median TNSS 8.5 1.9 8.3 1.8 8.1 1.7 7.9 7.7 1.6 7.5 1.5 Callergin No treatment Callergin No treatment Both, total nasal symptom score and runny nose, were s
Slide 21: Financials
Financials Full year results 2022 © Marinomed Biotech AG 21
Slide 22: Continuous double digit growth
Continuous double digit growth Strong Carragelose business and encouraging Solv4U development Y-o-Y comparison of quarterly revenues (m€) Comments Key growth drivers 11.6 11.3 * • Adjusted for the Budesolv milestone in 2021 (€1.9m), 5.9 4.1 revenues rose from €9.7m to €11.3m (+16.5%) 2.2 2.4 2.5 2.5
Slide 23: Solid cash position
Solid cash position Low cash drain due to profitable revenues and inflows from convertible bond program • Ended December 2021 with €5.8m in cash • Raised +€7.4m in net cash through EIB1 (€6.0m), NÖBEG2 (€0.2m) and CNFP3 (€1.2m) • Received +€0.7m in milestones • Earned +€3.9m net cash through profita
Slide 24: FY 2022 Statement of profit or loss (IFRS)
FY 2022 Statement of profit or loss (IFRS) Despite missed milestone, stable full year financials €m FY 2022 FY 2021 •1 Therein: FY 2022 FY 2021 Revenues 1 11.3 11.6 Sale of goods 10.5 9.0 Other income 2 0.8 1.6 Cost of goods sold -7.1 -6.1 Materials expenses -7.3 -6.4 Margin 32.3% 32.1% Services exp
Slide 25: Outlook
Outlook © Marinomed Biotech AG 25
Slide 26: Project status updates
Project status updates Project Status/next steps Tacrosolv Enter into a partnership within the next 9-18 months Immunology Budesolv Work on registration with Luoxin for Greater China; additional partnership for Europe (6-12 months) Autoimmune gastritis Preclinical research; apply for FFG grant Carra
Slide 27: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar 2023 May 23, 2023 Publication of the Results Q1 2023 Record Date for participation June 11, 2023 at the Annual General Meeting June 21, 2023 6th Annual General Meeting August 17, 2023 Publication of the Results H1 2023 Stephanie Kniep November 21, 2
Slide 28: www.marinomed.com
www.marinomed.com 0) Marinomed
Slide 29: Appendix
Appendix © Marinomed Biotech AG 29
Slide 30: Budesolv (MAM-1004-1)
Budesolv (MAM-1004-1) Nasal spray formulation of corticosteroid Budesonide for treating allergic rhinitis 7.6 • Marinosolv formulation: solution instead of suspension • Successful pivotal Phase III study 7.2 completed: • ~85% reduced dose • Significant faster onset of action 6.8 TNSS (<2h after trea
Slide 31: Carravin (MAM-2001-1)
Carravin (MAM-2001-1) Combination of Xylometazoline and Carrageenan • Active ingredient = Xylometazoline (decongestant) • Carrageenan supports Xylometazoline in reducing the duration and intensity of symptoms associated with viral infections of the respiratory tract • For the treatment of nasal cong
Slide 32: Sustainability
Sustainability Marinomed contributes to sustainability goals and adheres to ESG • Reduction of active ingredient by using Marinosolv solubilization technology • Sustainability of company premises (e.g., solar energy) • Promote environmentally friendly supply chains ENVIRONMENT • Therapies for people